Form 8-K - Current report:
SEC Accession No. 0001213900-24-094178
Filing Date
2024-11-04
Accepted
2024-11-04 17:00:10
Documents
14
Period of Report
2024-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021970901-8k_abvcbio.htm   iXBRL 8-K 30988
2 LETTER AGREEMENT ea021970901ex10-1_abvcbio.htm EX-10.1 34134
  Complete submission text file 0001213900-24-094178.txt   248849

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20241104.xsd EX-101.SCH 3021
4 XBRL LABEL FILE abvc-20241104_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abvc-20241104_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT ea021970901-8k_abvcbio_htm.xml XML 3570
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 241424501
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)